BCRX — BioCryst Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $2.22bn
- $2.74bn
- $450.71m
- 25
- 47
- 86
- 52
Annual income statement for BioCryst Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 17.8 | 157 | 271 | 331 | 451 |
| Cost of Revenue | |||||
| Gross Profit | 16.1 | 150 | 264 | 327 | 438 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 195 | 279 | 419 | 464 | 453 |
| Operating Profit | -177 | -122 | -148 | -133 | -2.54 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -183 | -182 | -244 | -226 | -87 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -183 | -184 | -247 | -227 | -88.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -183 | -184 | -247 | -227 | -88.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -183 | -184 | -247 | -227 | -88.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.08 | -1.23 | -1.33 | -1.08 | -0.43 |